Expertise in
13
conditions

Dr. Jennifer A. Dorth

Radiation Oncology
University Hospitals Portage Medical Center
6847 N Chestnut St, 
Ravenna, OH 
Accepting New Patients
Expertise in
13
conditions
University Hospitals Portage Medical Center
6847 N Chestnut St, 
Ravenna, OH 

Overview

Jennifer Dorth is a Radiation Oncologist practicing medicine in Ravenna, Ohio.

Dr. Dorth is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, Pancreatic Cancer, Prostate Cancer, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 13 clinical trials. Dr. Dorth is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in NC

Hospital Affiliations

Uh Cleveland Medical Center
University Hospitals Ahuja Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

University Hospitals Portage Medical Center
6847 N Chestnut St, Ravenna, OH 44266
Other Locations
University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
View 9 Less Clinical Trials

58 Total Publications

Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.
Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.
Journal: The oncologist
Published: December 24, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Michael A. Weller
Radiation Oncology
Expertise in
31
conditions
Dr. Michael A. Weller
Radiation Oncology
Referral may be required

Hillcrest Hospital

6780 Mayfield Rd, 
Mayfield Heights, OH 
 (25.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Weller is a Radiation Oncologist practicing medicine in Mayfield Heights, Ohio. Dr. Weller is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Thrombectomy, and Gamma Knife Radiosurgery.

Expertise in
51
conditions
Dr. Samuel Chao
Radiation Oncology
Expertise in
51
conditions
Dr. Samuel Chao
Radiation Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (29.5 miles away)
866-223-8100
Experience:
29+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Samuel Chao is a Radiation Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 29 years. Dr. Chao is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Astrocytoma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Chao is board certified in American Board Of Radiology, 2007. Dr. Chao is currently accepting new patients.

Expertise in
52
conditions
Dr. John H. Suh
Radiation Oncology
Expertise in
52
conditions
Dr. John H. Suh
Radiation Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (29.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Suh is a Radiation Oncologist practicing medicine in Cleveland, Ohio. Dr. Suh is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Astrocytoma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Suh is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer A. Dorth

How do I make an appointment with Dr. Jennifer A. Dorth?

You can book an appointment with Dr. Jennifer A. Dorth by calling their office at 216-844-3951. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer A. Dorth a top-rated expert for Squamous Cell Carcinoma of the Anal Canal (SCAC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer A. Dorth is classified as an Elite expert for Squamous Cell Carcinoma of the Anal Canal (SCAC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer A. Dorth specialize in?

While Dr. Jennifer A. Dorth is a Radiation Oncology, they have specific expertise in Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, and Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Jennifer A. Dorth participate in research or clinical trials?

Yes. Dr. Jennifer A. Dorth has published 58 articles and abstracts on conditions like Squamous Cell Carcinoma of the Anal Canal (SCAC). You can view a list of Dr. Jennifer A. Dorth's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer A. Dorth accept my insurance?

Dr. Jennifer A. Dorth accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 216-844-3951 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dorth's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 60 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile